Clinical trial NCT06645808: PET-imaging of Two Vartumabs in Patients With Solid Tumors
Official title: The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Solid Tumor
Colon Carcinoma
Rectal Carcinoma
Osteosarcoma
Chondrosarcoma
Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Esophageal Carcinoma
Gastric Carcinoma
Pancreas Carcinoma
Bladder Carcinoma
Glioblastoma
Keywords: Basket-trial
Oncology
Lead sponsor: Var2 Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: TRACER Europe BV
First posted: 2024-10-17
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Initially, three patients per compound (89Zr-C9scFv and 89Zr-F8scFv) will be included according to alternating inclusion or patient availability. Subsequently, an interim analysis will be conducted to determine the optimal radiation dose and optimal scanning day for each radiolabeled antibody fragment.

After the interim analysis, cohorts will be expanded by seven more subjects each, resulting in 20 subjects (2 x 10) total in the initial study across both cohorts. After completion of the initial study, each cohort may be further expanded by six subjects in additional indications, totaling (2 x 16) 32 patients. This basket trial aims to include at least one patient per indication.

For expansion cohort subjects, IMP-administration will occur on day 1, with one PET/CT scan performed on the most optimal day (day 1-7).
Primary purpose: OTHER

Brief summary: VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).

Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues.

VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.

Detailed description: VARTUTRACE aims to investigate the biodistribution and pharmacology in patients with solid tumors of two antibody fragments specific for oncofetal CS.

VAR2 Pharmaceuticals has identified and characterized oncofetal CS as a group of tumor-specific carbohydrate motifs that appear in placental tissue during fetal development and in most cancers while remaining largely absent from healthy tissue. VAR2 Pharmaceuticals recently developed a panel of antibodies specific for oncofetal CS and characterized their tumor specificity, therapeutic, and safety in pre-clinical models under various formats.

VARTUTRACE is a Phase 0 microdosing study of a single administration of \<30 nmol of one of the two most promising antibody fragments identified by VAR2 Pharmaceuticals - C9 and F8. Both antibody fragments will be used as short chain variable fragments (scFvs) labelled with the radioisotope Zirconium-89 (89Zr) and are therefore respectively named 89Zr-C9scFv or 89Zr-F8scFv. As it remains unclear from the pre-clinical in vitro and in vivo data which of the two will have the most optimal tumor targeting properties in patients with solid tumors, both scFvs will be evaluated.

The biodistribution, pharmacokinetics, pharmacodynamics, and clearance of two of these antibody fragments is planned to be studied in up to 32 patients with various cancers (i.e. a basket-trial).

Eligibility criteria: General Inclusion Criteria:

1. Willing to adhere to the prohibitions and restrictions specified in this protocol.
2. Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol.
3. Patients aged ≥ 18 years at moment of signing informed consent form.
4. Life expectancy of \> 12 weeks.
5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.
6. BMI ≥ 18.0 and ≤ 35.0 kg/m2 and weight at least 50 kg and no more than 120 kg at screening.
7. Overtly healthy based on medical history, physical findings, vital signs, ECG at the time of screening, as judged by the Investigator. Note: one retest of vital functions and ECG is allowed within the screening window.
8. Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit:

   * AST, ALT, and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN) as determined by the UMCG laboratory reference values.
   * Serum bilirubin ≤ 2.0x ULN as determined by the UMCG laboratory reference values. Patients with known Gilbert disease who have serum bilirubin level ≤ 3x ULN may be enrolled.
   * INR or APTT ≤ 1.5x ULN as determined by the UMCG laboratory reference values. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
   * eGFR (based on plasma-creatinine) = \>30 mL/min.
   * Serum albumin \>35 g/L.
9. No other clinically significant laboratory abnormalities as determined by the investigator. Note: one retest of lab tests is allowed within the screening window.
10. Female patients should be at least 1 year post-menopausal (amenorrhea \>12 months and/or follicle-stimulating hormone \>30 mIU/mL) at screening or surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation).
11. Male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control, and must not donate sperm, until 3 months after administration of 89Zr-DFO-N-Suc-scFv (F8 or C9).

Medical inclusion Criteria:

Colon Carcinoma:

1. Patients diagnosed with colon carcinoma stage I-IV, according to the 8th edition of the TNM-classification.
2. Histologically confirmed diagnosis of colon carcinoma.
3. Neo-adjuvant treatment according to the standard of care.

Rectal Carcinoma:

1. Patients diagnosed with rectal carcinoma stage I-IV, according to the 8th edition of the TNM-classification.
2. Histologically confirmed diagnosis of rectal carcinoma.
3. Neo-adjuvant treatment according to the standard of care.

Osteosarcoma:

1. Patients diagnosed with osteosarcoma stage I-IV, according to AJCC staging for Bone Sarcoma.
2. Histologically confirmed diagnosis of osteosarcoma.

4. Neo-adjuvant treatment according to the standard of care.

Chondrosarcoma:

1. Patients diagnosed with chondrosarcoma stage I-IV, according to AJCC staging for Bone Sarcoma.
2. Histologically confirmed diagnosis of chondrosarcoma.
3. Neo-adjuvant treatment according to the standard of care.

Lung Carcinoma:

1. Anticipated diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) stage I-IV, according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology.
2. Neo-adjuvant treatment according to the standard of care.

Head and Neck Squamous Cell carcinoma (HNSCC):

1. Patients diagnosed with HNSCC of the oral cavity, oropharynx, nasal cavity, nasopharynx, hypopharynx and larynx.
2. Histologically confirmed diagnosis of HNSCC.
3. Neo-adjuvant treatment according to the standard of care.

Oesophageal and gastric carcinoma:

1. Patients diagnosed with oesophagus carcinoma stage I-IV according to the 7th edition of the TNM-classification.
2. Patients diagnosed with gastric carcinoma stage I-IV according to the 7th edition of the TNM-classification.
3. Histologically confirmed diagnosis of oesophageal- or gastric carcinoma.
4. Neo-adjuvant treatment according to the standard of care.

Pancreas carcinoma:

1. Anticipated diagnosis of pancreas carcinoma stage I-IV according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)/CT or based on cytology.
2. Histologically or cytologically confirmed diagnosis of pancreas carcinoma.
3. Neo-adjuvant treatment according to the standard of care.

Bladder carcinoma:

1. Patients diagnosed with invasive bladder carcinoma stage I-IV according to the 7th edition of the TNM-classification.
2. Histologically confirmed diagnosis of bladder carcinoma.
3. Neo-adjuvant treatment according to the standard of care.

Glioblastoma:

1. Anticipated diagnosis of a high-grade glioma (glioblastoma, grade 4 according to the WHO classification) based on imaging modalities such as MRI and/or CT or a biopsy.
2. Karnofsky performance status of at least 70%.
3. Neo-adjuvant treatment according to the standard of care.

General Exclusion Criteria:

1. Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient\&#39;s ability to understand and cooperate with the study protocol.
2. Insufficient venous access for the study procedures.
3. Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates.
4. Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications.
5. Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device.

Medical Exclusion Criteria:

1. The existence of a second concomitant active malignancy or treatment for a second malignancy within 1 year prior to IMP-administration, except for localized basal or squamous cell cancer that has been cured at least 90 days before screening.
2. Cardiac impairment with an estimated LVEF \<35 % Prolonged QTcF (\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the investigator.
3. Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate. Note: One retest of vital functions is allowed within the screening window.
4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
5. Major surgical procedure other than for the included diagnosis within four weeks before IMPadministration. Disease-related procedures, e.g. the placement of a port-a-cath, placement of a drain,ERCP, are allowed.
6. Current evidence or history of bacterial, viral or fungal infections within 7 days before 89Zr-DFON-Suc-scFv (F8 or C9) administration as judged by the Investigator.

   * T \> 38.0°C or lab confirmed viral/bacterial/fungal infection (PCR) or symptoms suggestive of an infection)
   * Received oral or IV antibiotics within \<7 days before administration.
7. Any planned major surgery within the duration of the study (until follow-up visit) that is not related to the tumor, with the exception of any emergency surgeries.
8. Prior allogeneic bone marrow transplantation or solid organ transplant.
9. A history of anaphylaxis, history of allergic reaction(s), known allergy to one of the drugs or excipients administered as part of this study. Mild allergies without angio-edema or treatment need can be acceptable if deemed not of clinical significance (including allergy to animals or mild seasonal hay fever).
10. Any other diseases, metabolic dysfunction, physical examination finding, or clinically significant laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.

Primary outcomes:
measure: Biodistribution and pharmacokinetics of the radiolabeled IMP
timeFrame: Day 1, 2, and 4 after dosing
measure: Tumor-specific uptake of the IMP
timeFrame: Day 1 - 7 after dosing
measure: Incidence of treatment emergent adverse events (AE) (safety and tolerability)
timeFrame: Study duration (up to 56 days)
Secondary outcomes:
measure: Tumor-specific uptake of the IMP per cancer type
timeFrame: Day 1 -7 after dosing
Other outcomes:
measure: Presence of IMP and target in patient-derived tumor tissue
timeFrame: Day 1 - 7 after dosing
Locations:
city: Groningen
country: Netherlands
facility: University Medical Center Groningen (UMCG)
Study officials:
affiliation: TRACER Europe B.V.
name: Gooitzen van Dam, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: